Although substantial progress has been made with Ebola virus (EBOV) vaccine measures,
the immune correlates of vaccine-mediated protection remain uncertain. Here, five mucosal …

Summary The 2013 Ebola epidemic in Central and West Africa heralded the emergence of
wide-spread, highly pathogenic viruses. The successful recombinant vector vaccine against …

It has been proven challenging to conduct traditional efficacy trials for Ebola virus (EBOV)
vaccines. In the absence of efficacy data, immunobridging is an approach to infer the …

Background Several vaccine platforms have been successfully evaluated for prevention of
Ebola virus (EBOV) disease (EVD) in nonhuman primates and humans. Despite remarkable …

Antibodies are promising post-exposure therapies against emerging viruses, but which
antibody features and in vitro assays best forecast protection are unclear. Our international …

Evolution of antibody repertoire against the Ebola virus (EBOV) proteome was characterized
in an acutely infected patient receiving supportive care alone to elucidate virus-host …

Without clinical efficacy data, vaccine protective effect may be extrapolated from animals to
humans using an immunologic marker that correlates with protection in animals. This …

Ebola virus disease is a deadly infection which occurs in sporadic outbreaks. Several
vaccine candidates have been developed. The most advanced candidate is the recombinant …

The recent Ebola virus (EBOV) epidemic highlighted the need for effective vaccines and
therapeutics to limit and prevent outbreaks. Host antibodies against EBOV are critical for …

Ebola virus (EBOV) remains a public health threat. We performed a longitudinal study of B
cell responses to EBOV in four survivors of the 2014 West African outbreak. Infection …